colorimetric assay kits  (Elabscience Biotechnology)

Journal: Bioactive Materials

Article Title: Synergistic mitochondrial homeostasis regulation and cholinergic circuits reconstruction via a one-step synthesized multifunctional hydrogel facilitates spinal cord injury repair

doi: 10.1016/j.bioactmat.2025.12.009

Figure Lengend Snippet: ROS scavenging capabilities of the PLCS hydrogel. (A) Visual color changes of the ABTS + • solution after incubation with PLC and PLCS hydrogels over time. (B) and (C) UV–vis absorption spectra of ABTS + • solution following incubation with PLC and PLCS hydrogels at different time points. (D) Quantitative comparison of ABTS + • scavenging activity between PLC and PLCS hydrogels over time (n = 3). (E) and (F) UV–vis absorption spectra of •OH scavenging activity of PLC, PLCS hydrogels at different time points. (G) Statistical comparison of •OH scavenging efficiencies of PLC and PLCS hydrogels (n = 3). (H) O 2 • - scavenging ability of PLC and PLCS hydrogels over time (n = 3). (I) H 2 O 2 scavenging ability of PLC and PLCS hydrogels over time (n = 3). (J) Flow cytometric analysis of intracellular ROS levels using DCFH-DA staining in different treatment groups. (K) Quantification of DCFH-DA fluorescence intensity (n = 3). (L–N), Fluorescent microscopy images of PC12 cells stained with DCFH-DA, DHE, and DAPI after various treatments, along with corresponding fluorescence intensity quantification (n = 3). Statistically significant at ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, and ∗∗∗∗p < 0.0001.

Article Snippet: The specific procedures were as follows: First, 7 mM ABTS solution was thoroughly mixed with 2.45 mM potassium persulfate (K 2 S 2 O 8 ) (Macklin, China) solution and reacted overnight at 4 °C in the dark to generate a stable ABTS• + radical stock solution.

Techniques: Incubation, Comparison, Activity Assay, Staining, Fluorescence, Microscopy

Journal: bioRxiv

Article Title: A senescent iCAF-like fibroblast state governs therapy resistance in rheumatoid arthritis

doi: 10.64898/2026.04.17.718831

Figure Lengend Snippet: Elimination of senescent cells contributes to the alleviation of experimental synovitis. a , Differential gene expression analysis comparing synovial fibroblasts (SF) depleted of APOC1 or negative control. Blue points, genes with significantly decreased expression (false discovery rate (FDR) < 0.01); black labels, marker genes of p16 h -sn fibroblast from Meguro et al . b , Enrichment of p16 h -sn fibroblast marker genes in APOC1 -depleted SF relative to negative control, calculated by Gene Set Enrichment Analysis (GSEA) . c , Experimental design of the collagen antibody-induced arthritis (CAIA) mouse model using 7-8 week-old male p16-Cre ERT2 -DTR mice or p16-Cre ERT2 mice (control). Starting at the time of arthritis induction, mice received intraperitoneal injections of tamoxifen 80 mg/kg and diphtheria toxin 25 μ g/kg twice daily. d , Clinical arthritis scores of p16-Cre ERT2 -DTR mice (n = 12) and p16-Cre ERT2 control mice (n = 13) under CAIA condition. Dots, mean; error bars, SD. P values, two-tailed Mann-Whitney U test (* p <0.05). e , Ratio of eroded surface to total surface area of left ankle joints in p16-Cre ERT2 -DTR mice (n = 12) and p16-Cre ERT2 control mice (n = 13) under CAIA condition, assessed by micro-computed tomography (micro-CT). Bars, mean; error bars, SD. P values, two-tailed Mann-Whitney U test (* p <0.05). f , Experimental design of the CAIA mouse model using 7-week-old male DBA/1J wild-type mice treated with the TNF inhibitor etanercept and/or the senolytic agent ABT-263. Following arthritis onset, mice received intraperitoneal injections of vehicle or etanercept 2 mg/kg twice daily and oral administration of vehicle or ABT-263 100 mg/kg once daily. g , Clinical arthritis scores of mice treated with etanercept plus ABT-263 (n = 9), etanercept alone (n = 9), ABT-263 alone (n = 8) or vehicle (n = 9) under CAIA condition. Dots, mean; error bars, SD. P values, two-tailed Mann-Whitney U test (* p < 0.01 versus vehicle; # p < 0.05 for etanercept plus ABT-263 versus etanercept alone). h , Ratio of eroded surface to total surface area of left ankle joints in mice treated with etanercept plus ABT-263 (n = 9) or etanercept alone (n = 9) under CAIA condition, assessed by micro-CT. Bars, mean; error bars, SD. P values, two-tailed Mann-Whitney U test (* p <0.05). CAIA, collagen antibody-induced arthritis; CT, computed tomography; DT, diphtheria toxin; DTR, diphtheria toxin receptor; FDR, false discovery rate; GSEA, Gene Set Enrichment Analysis; ip, intraperitoneal; iv, intravenous; KO, knock out; LPS, lipopolysaccharide; po, per os; SD, standard deviation; SF, synovial fibroblast; sn, senescent.

Article Snippet: ABT-263 was dissolved in a vehicle consisting of ethanol (Fujifilm, 054-07225), polyethylene glycol 400 (BioUltra, 91893-250ML-F), and Phosal 50 PG (MedChem Express, HY-H1903) at a ratio of 10:30:60.

Techniques: Gene Expression, Negative Control, Expressing, Marker, Control, Two Tailed Test, MANN-WHITNEY, Micro-CT, Computed Tomography, Knock-Out, Standard Deviation

Journal: bioRxiv

Article Title: Sacituzumab Govitecan as an Effective Strategy for Sensitizing Chemoresistant HNSCC Cells to Senolytic Intervention

doi: 10.64898/2026.04.13.718209

Figure Lengend Snippet: (A) HN30 and HN30R cells were treated with either 0.9% saline vehicle or 0.2 μg/mL SG for 72 hours followed by treatment with either ABT-263 (1 μM), S63845 (0.1 μM), ABT-199 (1 μM), A- 1155463 (1 μM), or DMSO for 48 hours. Cells were then stained with 0.05% Crystal Violet to assess for cell viability. (B) HN30 and HN30R cells were treated with 0.2 μg/mL SG for 72 hours followed by 1 μM ABT-263 for 48 hours and assessed for apoptosis induction via Annexin-V/PI FACS; each treatment condition is representative for three biological replicates. **p < 0.01 .

Article Snippet: SN-38 (MedchemExpress, HY-13704), ABT-263 (MedchemExpress, HY-10087), S63845 (MedchemExpress, HY-100741), A-1155463 (MedchemExpress, HY-19725), and ABT-199 (MedchemExpress, HY-15531) were dissolved in DMSO.

Techniques: Saline, Staining

Journal: bioRxiv

Article Title: Sacituzumab Govitecan as an Effective Strategy for Sensitizing Chemoresistant HNSCC Cells to Senolytic Intervention

doi: 10.64898/2026.04.13.718209

Figure Lengend Snippet: (A) HN30 and HN30R cells were treated with 0.2 μg/mL SG for 72 hours followed by 1 μM ABT-263 for 48 hours and then harvested for total cell lysates. Fifty micrograms of protein were loaded for each sample for western blot analysis with the indicated antibodies. Densitometry was assessed via ImageJ quantification as described in . (B) HN30 shControl, shBAK, and shBAX cells were treated with 0.2 μg/mL SG for 72 hours followed by 1 μM ABT-263 for 48 hours and harvested for total cell lysates as described in ( A ). (C) HN30 shControl, shBAK, and shBAX cells were treated as described in ( B ) and evaluated for apoptosis induction via Annexin-V/PI FACS; each condition is representative of three biological replicates. **p < 0.01 .

Article Snippet: SN-38 (MedchemExpress, HY-13704), ABT-263 (MedchemExpress, HY-10087), S63845 (MedchemExpress, HY-100741), A-1155463 (MedchemExpress, HY-19725), and ABT-199 (MedchemExpress, HY-15531) were dissolved in DMSO.

Techniques: Western Blot

Journal: bioRxiv

Article Title: Sacituzumab Govitecan as an Effective Strategy for Sensitizing Chemoresistant HNSCC Cells to Senolytic Intervention

doi: 10.64898/2026.04.13.718209

Figure Lengend Snippet: (A) HN30R cells were treated with 0.2 μg/mL SG for 72 hours followed by 1 μM ABT- 263 for 48 hours and assessed for live cell count via trypan blue exclusion assay at the indicated timepoints. Each point represents the average of three biological replicates. Brackets display the treatment duration for SG and ABT-263. (B) HN30R cells were subcutaneously injected into the left cheek of NSG mice and treated with 0.25 mg/kg SG 1x weekly for 1 week followed by 80 mg/kg ABT-263 3x weekly for 1 week. Mice were randomized into either vehicle, SG, ABT-263, or SG+ABT-263 treatment groups ( n = 6 per group) once tumors reached approximately 50 mm 3 (Day 22). SG was administered via intraperitoneal injection on Day 22 while ABT-263 was given via oral gavage on Days 27, 29, and 31. (C) Tumor volume was assessed via caliper measurement while (B) overall survival over time was identified via Kaplan-Meier analysis. (D) Body weight was monitored throughout the study duration to assess drug toxicity. * p < 0.05, **p < 0.01, ***p<0.001 (vehicle vs. SG+ABT-263 treatment groups); error bars reflect the standard deviation for each point.

Article Snippet: SN-38 (MedchemExpress, HY-13704), ABT-263 (MedchemExpress, HY-10087), S63845 (MedchemExpress, HY-100741), A-1155463 (MedchemExpress, HY-19725), and ABT-199 (MedchemExpress, HY-15531) were dissolved in DMSO.

Techniques: Cell Characterization, Trypan Blue Exclusion Assay, Injection, Standard Deviation